- WKN: A2DKCH
- ISIN: NL0012169213
- Land: The Netherlands
Nachricht vom 19.10.2021 | 11:14
QIAGEN N.V.: Release of a capital market information
/ Share Repurchase
Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting
With disclosure dated September 22, 2021, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the beginning of a second tranche of up to USD 19.4 million starting on September 27, 2021 under the share repurchase program originally announced on July 12, 2021.
The number of shares which have been bought back within the framework of such tranche of the share repurchase program in the time period from October 11, 2021 until and including October 15, 2021, amounts to 96,894 shares.
Shares were bought back as follows:
The underlying individual trades are published on the website of QIAGEN N.V. (https://corporate.qiagen.com/investor-relations/stock-information/share-buyback/default.aspx).
The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from September 27, 2021 until and including October 15, 2021 amounts to 318,557 shares.
The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.
Venlo, 19 October 2021
|5912 PL Venlo|
|End of News||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
03. Dezember 07:23 Märkte am Morgen: DAX mit erneuter Erholungsbewegung; Apple, Moderna, ...
03. Dezember 07:33 Nordex schlägt in den USA zu - die Serie geht weiter
03. Dezember 07:40 Daimler: Starker Newsflow
03. Dezember 07:45 Charlie Munger warnt: Das ist noch verrückter als zur Dotcom-Zeit
03. Dezember 07:59 Capital Markets Day der Allianz: Das müssen Sie wissen
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021